Archive for October, 2020
Trxade Group (NASDAQ: MEDS), an integrated drug-procurement, delivery and health-care platform, assists pharmacies in cutting costs in an era where the pricing of medication poses a major challenge that significantly inflates health-care spending. Trxade’s pharmaceutical trading platform is designed to reduce costs, assisting smaller pharmacies to compete through providing radical price transparency and increased market competition. A recent article discussing this reads, “The online marketplace hosted by the Trxade Group offers pharmacies a real opportunity to reduce purchase costs. Called the Trxade¿Exchange, the platform gives small pharmacies access to the wider pharmaceutical distribution network, allowing them to search for and view products from manufacturers, buying groups¿and wholesalers on a real-time and continuous basis. By increasing competition and price transparency, the Trxade¿Exchange is giving today’s independent drugstores a new lease on life.”
To view the full article, visit: https://nnw.fm/4y832
About Trxade Group Inc.
Headquartered in Tampa, Florida, Trxade Group is an integrated drug-procurement, delivery and health-care platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making health-care services affordable and accessible. Founded in 2010, Trxade Group is comprised of four synergistic operating platforms: (1) the Trxade B2B trading platform with 11,725 registered pharmacies; (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division; (3) the Bonum Health platform offering affordable telehealth services; and (4) the DelivMeds app, which coordinates a nationwide distribution network through independent pharmacies or mail-order delivery. For additional information, please visit www.Trxade.com, www.DelivMeds.com and www.BonumHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent research report by Aegis Capital Corp. The report reads, “VistaGen is developing multiple therapeutic candidates for the treatment of anxiety, depression, and other CNS indications. VistaGen’s development pipeline includes PH94B, a neuroactive nasal spray targeting Social Anxiety Disorder (‘SAD’), among other conditions, PH10, an additional neuroactive nasal spray for indications including Major Depressive Disorder (‘MDD’), and AV-101 an oral drug for psychiatric and other CNS disorders. We believe Phase 2 data in PH94B and PH10 strongly supports proof of concept, including compelling safety and efficacy data that likely differentiate these assets from existing treatments in crucial ways that could be supportive of market adoption if and when approved.”
To view the full report, visit http://ibn.fm/eLamD
About VistaGen Therapeutics
VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Months after the coronavirus sprang onto the global arena and claimed a million lives worldwide, scientists are still scrambling to find a vaccine and ultimately, a cure. At the moment, there are around 40 different coronavirus vaccines in clinical trials, with about 240 vaccines in early development. One such study suggests that we may not even need an external vaccine after all and provides evidence that the seasonal colds you’ve had in the past could offer you protection against COVID-19.
On top of that, such immunity to the coronavirus may last a long time, maybe even your entire life, infectious disease experts at the University of Rochester Medical Center say. The study compared blood samples from two groups: 26 people who were recovering from mild to moderate coronavirus and 21 healthy donors whose samples were collected 6 to 10 years ago, long before they could have been infected by COVID-19.
The researchers measured levels of memory B cells, immune cells that can detect pathogens, create antibodies to destroy them, and remember them for the future. The study, published in mBio, found that SARS-CoV-2, the virus that causes COVID-19, induces memory B cells which can live for decades. Most common coronaviruses result in upper respiratory illnesses, and they each trigger memory B cells into action.
The authors of the study believe that this could mean anyone who has been infected by a common coronavirus, which is almost everyone, may develop some degree of immunity to the coronavirus. “When we looked at blood samples from people who were recovering from COVID-19, it looked like many of them had a pre-existing pool of memory B cells that could recognize SARS-CoV-2 and rapidly produce antibodies that could attack it,” says lead study author Mark Sangster, Ph.D., a research professor of Microbiology and Immunology at URMC.
This is the first study to report cross-reactivity of memory B cells, meaning memory B cells that once neutralized cold-causing coronaviruses recognizing SARS-CoV-2 and springing into action. The cells produce antibodies that attack specific parts of the Spike Protein, a key protein used by the coronavirus to invade human cells. Although the Spike Protein looks and acts a little different in each coronavirus, one of its components dubbed the S2 subunit is the same across all the viruses.
The study found that in beta coronaviruses, a subclass that includes SARS, MERS, SARS-CoV-2 as well as two common colds, memory B cells can’t tell the difference between the Spike S2 subunits of different coronaviruses and attacks indiscriminately.
According to David Topham, PhD., the Marie Curran Wilson and Joseph Chamberlain Wilson, Professor of Microbiology and Immunology at URMC, the next step is to determine the level of protection provided by cross-reactive memory B cells and how it impacts patient outcomes. “Now we need to see if having this pool of pre-existing memory B cells correlates with milder symptoms and shorter disease course, or if it helps boost the effectiveness of COVID-19 vaccines.”
This is research that biomedical sector players like VistaGen Therapeutics Inc. (NASDAQ: VTGN) are likely to follow since it suggests that the COVID-19 problem may not be such a long-term threat as had been originally thought.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, today announced that its wholly owned subsidiary, Mulch Manufacturing Inc., has obtained 2021 mulch contracts from three Circle K convenience store divisions, a subsidiary of Alimentation Couche-Tard Inc. (OTC: ANCUF). This follows after the company secured a mulch and soil purchase agreement with The Kroger Company (NYSE: KR). “Obtaining three Circle K convenience store’s mulch contracts for 2021 gives us an amazing opportunity to build a relationship with their brand and expand throughout more stores,” SGTM’s CEO and Director Tony Raynor said in the news release. “We have been blessed to be offered these amazing opportunities from large chain accounts to help further expand our brand and overall exposure.”
To view the full press release, visit: https://nnw.fm/ajPVI
About Sustainable Green Team Ltd.
Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential, and commercial clients. For information regarding SGTM’s operations, expansion plans and production facilities, visit http://nnw.fm/3iVHn
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://nnw.fm/SGTM
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, today announced the appointment of retail industry veteran Frank Lazaran to its board of directors, effective Oct. 8, 2020. Lazaran will serve on the company’s audit and compensation committees. Simultaneous to the appointment, Bruce Leitch has decided to step down from the company’s board of directors to focus on other business endeavors. “On behalf of the board, we are delighted to welcome Frank Lazaran as a full-time member of The Alkaline Water Company’s Board of Directors,” WTER Chairman of the Board Aaron Keay said in the news release. “Frank is a seasoned industry veteran with experience and knowledge that will be instrumental as we scale our growing lifestyle brands to existing and new trade channels. Also, we want to thank Bruce for his outstanding leadership and guidance since 2016. His various contributions have helped to drive growth and innovation for our core brand, Alkaline88(R), and our emerging portfolio of A88 Infused(TM) and A88CBD(TM) products.”
To view the full press release, visit http://cnw.fm/pDIvC
About The Alkaline Water Company Inc.
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. Based out of South San Francisco, California, the “Birthplace of Biotechnology,” VistaGen is headquartered among the largest cluster of biotechnology companies in the world. A recent article discussing the company reads, “VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of VistaGen’s three drug candidates offers significant commercialization potential in multiple large CNS markets.”
To view the full article, visit: https://ibn.fm/N9ZB3
About VistaGen
VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- SRAX has announced acquisition of LD Micro, a leading data company serving small and micro-cap listed company space
- SRAX will pay gross consideration of 1.6 million new SRAX shares along with four $1 million installments
- Following acquisition, LD Micro will be wholly-owned subsidiary of SRAX and will continue to employ Christopher Lahiji, its founder, as president
- Christopher Lahiji has also been named to SRAX Board of Directors
SRAX (NASDAQ: SRAX), a financial technology company focused on unlocking data and insights for publicly traded companies through Sequire, its SaaS platform, announced that it had recently closed the acquisition of LD Micro, a leading data and event company serving the small and micro-cap space (https://nnw.fm/BhE2C). SRAX will pay a total consideration of 1.6 million new Class A SRAX common shares to LD Micro’s shareholders, which will be subject to a 36-month lock-up in addition to four quarterly installments of $1 million, with the first payment made upon the closing of the acquisition.
LD Micro was founded in 2006 with the purpose of providing investors with an independent resource into the listed micro-cap space. What started out as a newsletter highlighting unique companies eventually transformed into several influential events, which have firmly entrenched themselves as must-attend occasions for members of the listed micro-cap universe and institutional investors alike. Separately, LD Micro also launched ldmicro.com, a portal providing exclusive intraday information on the entire sector, including the first pure micro-cap index (LDMi) which covers stocks in North America boasting market capitalizations between $50 million to $300 million.
In early September, LD Micro held its flagship Main Event conference, which attracted over 1,500 delegates and hosted close to 300 innovative companies derived from a variety of sectors, including technology, biotech, pharmaceuticals, and alternative energy among various others. In illustration of the considerable breadth of the company’s flagship conference, the event featured a number of keynote addresses focused around noteworthy updates within the IPO market for North American microcaps. Discussions centered around the evolution of cryptocurrency as well updates from the Securities & Exchange Commission on recent regulatory developments within the listed microcap equity universe.
Following the acquisition, LD Micro will become a wholly-owned subsidiary of SRAX and will continue to employ Christopher Lahiji, its founder, as president. Mr. Lahiji has also been appointed to the board of directors of SRAX.
A more comprehensive description of the terms and conditions of the transaction is disclosed, and copies of the transaction documents are filed, in the Company’s current report on Form 8-K filed with the Securities Exchange Commission on September 11, 2020, which is available on the Company’s website and at www.SEC.gov.
For more information, visit the company’s website at www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
It doesn’t matter if you’re looking at small cap penny stocks or larger cap ones, if they’re trending, someone’s watching. The name of the game with these cheap stocks is simple: make money quickly. Some choose to map out a strategy for day trading and scalping while others focus on longer-term swing trading or even investing in penny stocks . It’s important to understand that if you’re looking to navigate these volatile waters, a strategy is important.
This is why I mention mapping out how you’re going to approach a trade or investment. The fact of the matter is that these mostly small cap stocks are known to shift direction quickly. As such, your strategy could dictate how you put together your penny stocks list to watch. If you’re a day trader or scalper, you’re likely looking for stocks that are experiencing higher levels of volatility.
However, if you’re looking more long term then you’ll want to focus on penny stocks with a more established trend and companies with stronger fundamentals. Now, not all penny stocks are going to “play out” to your plan’s design. However, taking the time to do your research can help put a sound list of penny stocks together. Then it’s up to the market to decide what’s next.
Obviously, when it comes to things like pre market penny stocks gapping up , everything can change right at the opening bell. In that case, prudent traders might wait to see how the first 15-30 minutes of a trading session pans out. Heading into the second half of the week, there are several penny stocks trading higher. Will they be on your buy or sell list?
Penny Stocks To Buy [or sell]: CVD Equipment Corp
Shares of CVD Equipment Corp. ( CVV Stock Report ) were trending much higher on Wednesday. It wasn’t much of a hype-spike as it was a consistent move higher. From the opening bell to its initial lunch time high, CVV stock rallied from $3 to $5.25. There weren’t any news headlines to pair with the move. However, we have seen a lot of attention placed on industrials stocks moving in the stock market today.
Read More
CVD focuses on a broad range of chemical vapor deposition, gas control, and other equipment to develop and manufacture materials and coatings. This equipment is used for aerospace engine components, medical implants, semiconductors, solar cells, smart glass among other applications.
WIth stocks like PECK, PPSI, SPI, SUNW and many others soaring today, CVV stock could be gaining some sympathy amid industrials this week. It mirrors some of the similarities from share structure as the stocks I just mentioned. Namely, it’s a low float industrial penny stock to watch. Given this, CVV could also be one of the more volatile names on this list. In light of that, be well aware that this could swing in either direction aggressively so keep your strategy in mind.
Penny Stocks To Buy [or sell]: ReneSola
RenaSola ( SOL Stock Report ) is another one of the industrials penny stocks gaining on sympathy momentum this week. In fact, for the better part of the last few months, SOL stock has managed to hold a relatively clear uptrend. But as I’m sure you’ll see, the penny stock’s ups and downs are very much a thing to assess if this is on your list of penny stocks to watch. Since Monday, SOL stock has jumped over 75% alone and volume has surged.
While it isn’t as low float a penny stock as the others, the company has responded similarly with surging momentum amid this latest sympathy move. Something to note, however, is that the company has also come out with some news of its own within the last few weeks.
At the end of September, the solar project developer agreed to form a joint venture with Munich, Germany-based Vodasun. The two will co-develop and market ready-to-build ground-mounted solar projects in Germany. This venture will have an initial project portfolio of 50 to 100 megawatts. There’s also a target of another 50 to 100 megawatts of new projects per year. With such a massive swing higher this week, can SOL stock maintain at these higher levels or is it set to sell-off before the end of the week?
Penny Stocks To Buy [or sell]: Checkpoint Therapeutics
What list of penny stocks would be complete without some biotech stocks ? Checkpoint Therapeutics Inc. ( CKPT Stock Report ) has been able to experience a nice technical move over the last few weeks. Shares pulled back from recent $4.50 highs after the company announced a $20 million raise in mid-September. Finally finding some support along its 50-day moving average, CKPT stock held a sideways trend for the bulk of September’s second half. However, as October has begun, so to appears to be a slight uptrend in the penny stock. On October 7th, shares bounced to highs of $2.82 during the mid-afternoon session.
[Read More] 5 Penny Stocks To Buy, Sell, Or Hold Right Now According To Analysts
Volume isn’t as heavy as it has been in the past. However, CKPT stock has managed to mount a recovery so far. The company was founded by Fortress Biotech ( FBIO Stock Report ) has followed the trend in cancer and immunotherapy stocks we’ve seen recently. Checkpoint develops, acquires, and commercializes non-chemotherapy, combination treatments. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX).
The company’s last update on its ongoing Phase 1 trials showed meaningful results according to the company. The trial studies its cosibelimab treatment, in patients with advanced cancers. Checkpoint explained that cosibelimab “demonstrated a 51.4% objective response rate and 13.5% complete response rate, which is nearly double the complete response rate observed at the time of previous analysis.”
Penny Stocks To Buy [or sell]: Sigma Labs Inc.
Sigma Labs Inc. ( SGLB Stock Report ) is another one of the top trending penny stocks to watch recently. The company hit the radar back in August after the company announced the award of a contract by Mitsubishi Heavy Industries. Sigma will implement PrintRite3D® in-process quality assurance software.
One of the other trends we’re seeing in the stock market today is in 3D printing believe it or not. Companies like 3D Systems Inc. ( DDD Stock Report ) and Stratasys ( SSYS Stock Report ) gained traction on Wednesday. Whether or not this is a sympathy-type move is yet to be seen. However, SGLB stock has pushed higher during Wednesday’s session on higher volume.
In addition to Mitsubishi, Sigma announced earlier this week that it launched its newest product, the PrintRite3D Lite In-Process Quality Assurance system. Furthermore, it was awarded its first contract from Coherent, Inc. ( COHR Stock Report ). Coherent is one of the world’s top providers of lasers and laser-based technology for scientific, commercial, and industrial customers.
Processa Pharmaceuticals (NASDAQ: PCSA) has closed its previously announced underwritten public offering of 4,800,000 shares of common stock, which were offered to the public for $4 per share. The clinical-stage biopharmaceutical company, which focuses on the development of drug products intended to provide treatment for and improve the survival and/or quality of life of patients who have a high unmet medical need condition or who have no alternative treatment, announced that the public offering resulted in gross proceeds of approximately $19.2 million. PCSA has filed a registration statement relating to the securities being sold with the Securities and Exchange Commission (“SEC”); the filing was effective on Oct. 1, 2020. A final prospectus has also been filed with the SEC. Copies of the final prospectus may be obtained from the Craig-Hallum Capital Group, which acted as joint book-running managers for the offering, along with The Benchmark Company. National Securities Corporation acted as co-manager for the offering.
To view the full press release, visit http://ibn.fm/0thEx
About Processa Pharmaceuticals Inc.
The mission of Processa has been to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions, medical conditions where patients need treatment options that will improve survival and/or quality of life. The company has assembled a proven regulatory science development team, management team and Board of Directors. The Processa development team has been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings. For more information, visit www.ProcessaPharmaceuticals.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at http://ibn.fm/PCSA
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
It is a well-known fact that electricity and water do not go well together. Most electronics shouldn’t be put in water and manufacturers constantly caution consumers against using their electronics in or near a wet environment. And for the most part, it’s not that hard to keep your toaster, television, or hairdryer away from water. But what if you are driving an electric vehicle (“EV”) and have to charge in the rain?
Electric vehicles are set to phase out internal combustion vehicles over the next decade or two. Although the technology behind EVs is decades old, the industry is still relatively new, and prospective customers as well as those who are just curious have plenty of questions. If you are thinking of purchasing an EV, the thought of running out of charge on a rainy day may have crossed your mind.
And if you paid attention to your parents and teachers as a child, you’re probably wary of going out into the soaking rain and plugging your electric vehicle into a charger. Maybe you’ll be electrocuted, maybe the car will explode: the possibilities seem endless. However, electric vehicle manufacturers took this into consideration, and consequently, most if not all EVs on the market can indeed be charged in the rain.
According to Jonathan Ratliff, Nissan North America’s senior manager for zero-emission technology development, he has heard this question “many many times” while spending years working on zero-emission vehicles. Because electric vehicles are purposefully engineered to withstand rain and water intrusion as well as dust particles that could wreak havoc on the electric system, he says, “it is safe to charge in nearly any weather condition.”
Like most items used in daily life like smartphones, wall outlets, and kitchen appliances, electric vehicles are subject to an Ingress Protection Rating, usually expressed in two digits. The first digit relates to small objects like dust particles or dirt while the second relates to protection against water and liquids. Ratcliff states that the rating scale for dust/solid object protection extends from 1-6, with 6 being the best protection while the scale for liquids ranges from 1-8, with 8 being the highest protection.
“An IP rating for 8 would be submersible and oceanic equipment, something underwater for a long, long time. Buoys are typically what you get in an 8 rating,” he says. The Nissan Leaf, for instance, has an IP rating of 67 and according to Ratliff, that is equivalent “to submerging any component of our vehicle in water at 1 meter for 30 minutes.” If the EV can withstand this level of submersion for up to thirty minutes, you can be sure it can withstand a little rainfall while it charges. It is no wonder that entities like Net Element (NASDAQ: NETE) are in full support of switching to electric vehicles since every possible precaution to keep them safe was taken by manufacturers.
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, is slated to present at an upcoming LD Micro virtual event. GNPX’s Zoom presentation is scheduled for Wednesday, Oct. 14, at 11 a.m. ET. The presentation will feature Genprex president and CEO Rodney Varner, who will deliver a corporate presentation and then participate in a Q&A. Investors and others interested in viewing the presentation can register at https://ibn.fm/MiDEy.
To view the full press release, visit http://ibn.fm/RdBSZ
About Genprex Inc.
Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Today, it is common to see members of a female soccer team training close to the ground that is being used by their male counterparts, and this is pleasing given how far society has come before accepting that females can participate in contact sports. However, lots of sports scientists noticed that females were complaining more about the effects of heading the ball when compared to their male counterparts. It now turns out that there is a scientific reason for that as explored below.
According to a study that was led by Dr. Michael Lipton, a neuroscientist based at the Albert Einstein College of Medicine, women suffer five times the amount of brain damage as males who head the ball during soccer games. The study also found that women take longer to recover from the resultant injuries sustained during sports.
The research team used MRI scans to take a look into the brains of 98 amateur soccer players, all of them adults. Half of them were male while the other half were female. These study subjects were selected on the basis of having headed the ball multiple times within the past year.
The scans done on the female soccer players showed some structural deterioration in eight white matter regions involved in carrying signals from one part of the brain to another. However, the male soccer players only had damage in three white matter regions. For both genders, the number of affected regions increased with an increase in the frequency of heading the ball.
When the volume of damaged brain tissue was analyzed, it was found that the female players suffered damage in about 2,100 cubic millimeters of the brain’s tissues while males only suffered damage in approximately 400 cubic millimeters.
The research team wasn’t sure why these sex differences exist regarding athletes heading the ball. However, they speculate that two factors could be at play.
First, Dr. Lipton and his team suggest that since women have less muscle mass to protect their heads from cranial impacts, they tend to suffer higher degrees of whiplash each time they head the ball.
Secondly, women could suffer more inflammation in the brain if they head the ball at the time in their menstrual cycles when progesterone is low. Progesterone is known to protect against brain inflammation, so a dip in this hormone makes females more susceptible to intracranial injuries each time they head the ball.
The research team is now interested in finding out whether the damage suffered while heading the ball is linked to any long-term cognitive effects. In the meantime, experts think biomedical companies like DarioHealth Corp. (NASDAQ: DRIO) would recommend taking any protective measures necessary to avert as many of those intracranial injuries as possible during soccer games.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a leading producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China, today announced a strategic collaboration. According to the update, Fujian Youth Hand in Hand Educational Technology Co. Ltd, a joint venture Blue Hat formed with a third party (“Fujian Youth” or the “JV”) and Guangzhou Tongsheng Education Technology Ltd. (“Tongsheng Education”) have reached an agreement to provide Augmented Reality Immersive Classes (“ARIC”) in Guangzhou over a three-year period. The JV will partner with Tongsheng Education with a goal to launch ARIC in a total of 320 preschools (20 the first year, 100 the second year and 200 the third year) in Guangzhou over a course of three years. The move begins Blue Hat’s strategic expansion in the Guangdong -Hong Kong-Macao Greater Bay Area (the “Greater Bay Area”). “This agreement allows us to further strengthen our market presence in the education sector, which along with augmented reality toys and games, are the three main pillars of Blue Hat’s business model,” BHAT CEO Xiaodong Chen said in the news release. “Our ARIC products have been well received since they were introduced to the market. At present, we have actively promoted them in Guangxi, Guangdong and other provinces and continue to build market share and expand our markets geographically. This cooperation provides a solid foundation for continued marketing efforts in the Greater Bay Area. With the continued development of education informatization in the Greater Bay Area and the growing demand for innovative teaching, we are confident to complete the goal of delivering ARIC services to 320 Guangzhou preschools in three years.”
To view the full press release, visit: https://nnw.fm/3oiQU
About Blue Hat
Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China, including interactive educational materials, mobile games and toys with mobile-game features. The company’s entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the company’s investor relations website at www.IR.BlueHatGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://nnw.fm/BHAT
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
October 7, 2020
Rritual Mushrooms, a premium brand in the emerging functional mushroom market, has announced that it has selected InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, for its communication needs. Founded in 2019, Rritual Mushrooms is a private company with a declared purpose to help people meet the demands of modern life with style and ease by incorporating functional mushrooms, adaptogens and superfoods into their diets. Rritual Mushrooms engaged IBN to leverage its investor-based distribution network of more than 5,000 key syndication outlets, social media channels, wire services and more to tell the Rritual story. That story includes Rritual’s ability to manufacture premium plant-based products such as small-batch elixir powders and meet the needs of customers from every lifestyle. “As it is yet in its early stages, the functional mushrooms market is rife with opportunities for growth,” said IBN director of client solutions Chris Johnson in the press release. “Although the global functional mushroom market is expected to exceed $50 billion by 2025, there remains an absence of a premium brand to lead the category. We’re excited to customize our comprehensive suite of corporate communications solutions for Rritual as it looks to capitalize on this opportunity.”
To view the full press release, visit https://nnw.fm/fLV6f
About Rritual Mushrooms Inc.
Launched in 2019, Rritual makes premium, plant-based elixir products in small batches featuring mindfully selected medicinal mushrooms and adaptogenic herbs. To help support and achieve an optimal need-state, Rritual offers a range of products to fit every lifestyle. Rritual produces simple mushroom adaptogen products with limited, yet very purposeful and organic ingredients. For more information about the company, visit www.WeAreRritual.com.
NOTE TO INVESTORS: The latest news and updates relating to Rritual Mushrooms are available in the company’s newsroom at https://nnw.fm/Rritual
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
October 7, 2020
KBL Merger Corp. IV (NASDAQ: KBLM), a special purpose acquisition company (“SPAC”) that previously entered a definitive agreement to acquire 180 Life Sciences, a clinical-stage biotechnology company, on Tuesday announced continued expansion of 180 Life Sciences’ robust intellectual property (“IP”) portfolio. According to the update, 180 Life Sciences is an applicant and licensee of a broad and growing patent portfolio for three major drug platforms in the areas of inflammation, fibrosis and pain. The portfolio covers 14 patent families with 42 patents issued and 32 pending in several important jurisdictions, including the United States, Canada, Europe, Australia, Japan and China. Of the many recent filings and grants in the company’s extensive portfolio, the EU Patent and Trademark Office in June 2020 granted patent number 2547363 “Methods of Prevention or Treatment of Triggered Inflammatory Reactions Using TNF Alpha Antagonist.” “The issuance of our European patents significantly strengthens the IP portfolio governing our lead program,” Dr. James Woody, CEO of 180 Life Sciences, said in the news release. “We are committed to broadening our global patent estate as we continue to expand our internal pipeline and increase patient access to innovative therapies. Having this most recent patent awarded in the EU is important as it provides validation in the 12 largest countries in the EU, including the UK, and provides the platform to be able to expand clinical trials, commercialization and partnering efforts throughout Europe. We look forward to achieving additional milestones by the end of 2020.”
To view the full press release, visit https://nnw.fm/tKEnj
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF, with its lead program in phase 2b/3 clinical trials. For more information, visit the company’s website at www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://nnw.fm/180
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
HANOVER, MD, Oct. 06, 2020 — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the survival and/or quality of life of patients who have a high unmet medical need condition or who have no alternative treatment, announced today the closing of its previously announced underwritten public offering of 4,800,000 shares of common stock for a price to the public of $4.00 per share. Gross proceeds to the Company were approximately $19.2 million.
Craig-Hallum Capital Group and The Benchmark Company acted as joint book-running managers for the offering. National Securities Corporation acted as co-manager for the offering.
A registration statement relating to the securities being sold in this offering was filed with the Securities and Exchange Commission (SEC) and became effective on October 1, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the shares of common stock described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The final prospectus has been filed with the SEC and electronic copies of the final prospectus may be obtained by contacting Craig-Hallum Capital Group at 222 South Ninth Street, Suite 350, Minneapolis, Minnesota 55402, Attention: Equity Capital Markets, by telephone at 612-334-6300, by email prospectus@chlm.com , or by accessing the SEC’s website, www.sec.gov .
About Processa Pharmaceuticals, Inc.
The mission of Processa has been to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions, medical conditions where patients need treatment options that will improve survival and/or quality of life. The Company has assembled a proven regulatory science development team, management team, and Board of Directors. The Processa development team has been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings.
Forward-Looking Statements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the registration statement relating to the securities being sold in this offering, which identifies important risk factors which could cause actual results to differ from those contained in the forward-looking statements.
# # #
For More Information:
Patrick Lin
plin@processapharma.com
925-683-3218
The human gastrointestinal tract has a diverse population of microorganisms, especially bacteria, fungi, and viruses. These are collectively referred to as the microbiota. Some of these colonies are passed on from mother to child during birth through the vaginal canal. However, babies who are born by cesarean section miss out on this microbiota transfer, and that puts their long-term health at risk since they will be more susceptible to immune-related complications later in life. Now a team of researchers has discovered that a mother’s microbiota can be transferred to an infant after birth through a procedure called fecal microbiota transplantation (“FMT”).
This procedure starts with a mother’s fecal matter being screened for dangerous pathogens and when none are found, the fecal matter is orally transplanted into the infant so that the baby can develop colonies of the same microbes that the biological mother of that infant has in their gut.
During the study, a team of researchers from mainly Helsinki University got fecal samples from seventeen mothers who had delivered by C-section. When those samples were checked for potentially dangerous microbes, only seven samples were found to be safe for oral transplantation to the infants.
The infants were then given the fecal samples orally and they were monitored for any adverse reactions. None were observed. The team then compared the microbes in the guts of those infants with those of other C-section infants who hadn’t got the FMT, as well as the microbiota of infants who had been born vaginally.
Over the three months of observation, the researchers found that the gut microbiota of the FMT babies quickly resembled that of the babies born vaginally while the gut microbes of the other C-section babies who didn’t receive the FMT retained the composition observed at birth.
The researchers concluded that fecal microbiota transplantation after C-section birth was a safe and viable way to confer the benefits of a mother’s microbiota to an infant who would have otherwise missed out on those protective benefits due to not being born vaginally.
This isn’t the first time that fecal microbiota transplantation has been used. The intervention has been used with great success to restore the gut microbiota of adults, as well as to cure a number of health conditions, such as persistent clostridium difficile infections.
The use of this same technique to lower the risk of C-section babies later developing chronic health conditions is therefore a welcome application of FMT, and biomed companies like VistaGen Therapeutics Inc. (NASDAQ: VTGN) are certainly glad that C-section babies can have a chance to fix the microbiota deficiency they exhibit as a result of their method of birth.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Months into the coronavirus and amidst the biggest economic crisis the state has seen in a century, Washington State’s marijuana industry is going strong. Dispensaries saw a “pretty big spike” in sales in March that is still continuing into September, says David Morgan, co-owner of Lucky Leaf in downtown Spokane. With the legislature adjourned at the moment, a legislative committee that oversees the industry is considering a variety of industry reforms including increasing the amount of information on product labels, as well as keeping track of the growing number of studies supported by marijuana sales tax.
During a recent work session to study major issues faced by the state’s marijuana industry, the House Commerce and Gaming Committee gathered information on whether to provide more information about the main chemical compounds in cannabis on product labeling. Although the plant produces over 200 cannabinoids, the two most dominant and the ones found in most cannabis products are THC and CBD. THC is responsible for marijuana’s infamous “high” while cannabidiol is known to induce health benefits such as relieving pain and anxiety and combating insomnia.
The committee also looked into the state’s current limits in potency for certain products. At the moment, Washington State limits the amount of THC in a single serving of any edible product to 10 milligrams with no more than 10 such servings per package. The legislature could consider limiting the amount of THC in cannabis concentrates to 10% next year, but a bill on that subject did not make it out of committee in this year’s session.
The committee was also appraised of the studies funded by taxes imposed on cannabis sales. Washington State University (“WSU”), for instance, has a range of studies that include crime, health, agriculture, and economics, and it has been charged with studying the effects of marijuana on pregnancy and adolescence. According to Ryan McLaughlin of the Department of Integrative Psychology and Neuroscience, researchers from WSU have developed an innovative way to use rats to simulate how people consume marijuana.
A rat is placed in a small chamber that allows it to push its nose through an opening, triggering the release of cannabis extract vapor. This allows researchers to see if adolescent rats develop a preference for extracts with more THC than CBD and how the use triggers changes in the brain as they grow, McLaughlin says. Celestine Barbosa-Leiker, vice chancellor for research at WSU Health Sciences Spokane, told the committee that marijuana use among pregnant women has doubled between 2012 and 2017.
A lot of pregnant women confessed that they regularly smoke marijuana to combat morning sickness, alleviate pain, and to help them sleep. However, they were getting mixed messages from health care providers, Barbosa-Leiker says, and they were doing their own research. “They’re relying on budtenders for their scientific and medical information.”
Industry watchers say that the research-based approach to decision making in Washington State is supported by cannabis companies like The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) who prefer policymakers that are informed while they do their work.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, today announced that its A88 Infused(TM) brand is gaining ground in the fast-growing flavored water market. According to the update, A88 Infused flavored water is widely available through multiple channel partners across various trades. “Demand for our single-serve offerings are at an all-time high, and we are rapidly growing shelf space for our A88 Infused flavored waters,” WTER president and CEO Ricky Wright said in the press release. “Our channel partners are some of the leading players in the all-natural vertical and give us a reach into nearly 40,000 retailers nationwide. Our sales team is working closely with our partners to create ‘speed-to-market’ programs, including promotion and incentives to drive further momentum. We are doing a great job creating new leads, and currently, our flavors are carried by or have placement commitments from nearly 13,200 stores across the U.S. Also, initial interest in our recently launched innovative offering, A88CBD infused Lemon-Lime flavored water, is strong, and we expect the SKU to be very appealing to the retail category buyers. Our A88 Infused brand is now available in some of the top supermarkets, retailers, and wholesalers, and we expect this trend to accelerate throughout our fiscal year.”
To view the full press release, visit http://cnw.fm/1xmiW
About The Alkaline Water Company
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium producer in the United States, today announced that the company became debt-free following the retirement of its remaining C$10,430,000 of floating-rate convertible unsecured subordinated debentures (the ” Debentures “). As of today, no Debentures remain outstanding, and they have ceased to be listed on the Toronto Stock Exchange. Further, Energy Fuels currently has no other remaining short- or long-term debt. “While many uranium and other natural resource companies have significant debt burdens, Energy Fuels is proud to announce that today we became debt free,” Mark S. Chalmers, president and CEO of Energy Fuels, said in the news release. “Being debt-free distinguishes Energy Fuels not only from many of our peers in the uranium and natural resource sectors, but also from many public companies in general. Having no debt reduces costs and allows Energy Fuels to better weather market volatility. Coupled with our strong working capital position, this also provides us with a ‘clean slate’ from which to increase uranium production when warranted and to launch the exciting rare-earth-element initiative we are pursuing.”
To view the full press release, visit http://ibn.fm/4jQIi
About Energy Fuels Inc.
Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant. Its corporate offices are near Denver, Colorado, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the United States today, has a licensed capacity of over 8 million pounds of U3O8 per year and has the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also currently on standby. In addition to the above production facilities, Energy Fuels has one of the largest NI 43-101 compliant uranium resource portfolios in the United States, including several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol UUUU; the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol EFR. For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced that it will present at the Alliance for Regenerative Medicine’s (“ARM”) virtual Cell and Gene Meeting on the Mesa, which is set to take place October 12-16, 2020. Genprex’s executive vice president and COO Michael Redman will lead the company’s presentation. The 2020 event will be delivered in a virtual format over the course of five days and feature on-demand company presentations and live-streaming panels. The Cell and Gene Meeting on the Mesa is the sector’s foremost annual conference, bringing together senior executives and top industry decision makers to advance cutting-edge research into cures. Tackling commercialization hurdles currently facing the cell and gene therapy sector, the conference covers a wide range of topics from clinical trial design to alternative, scalable payment models and supply chain platforms for advanced therapies. Interested parties should visit https://ibn.fm/ruXcY for more information or to register for the event.
To view the full press release, visit: https://ibn.fm/kX4bh
About Genprex Inc.
Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “GPX-001” (“quaratusugene ozeplasmid”), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s “Tagrisso(R)”) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information about the company, visit www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- Mullen Technologies begins built-out of pilot facility, accepting orders for MX-05 SUV.
- Facility slated for April 2021 completion; first MX-05 SUVs rolling off production line by Q2 2022.
- In August, Net Element, Mullen Technologies announced execution of definitive agreement to merge.
The announcement by Mullen Technologies Inc. that it has begun to build out its pilot manufacturing facility and take pre-orders for its M05 fully electric SUV bodes well for Net Element (NASDAQ: NETE). Earlier this year, Net Element, a global financial technology and value-added solutions group, and Mullen Technologies announced a merger agreement—so good news for Mullen means good news for Net Element.
“We are excited to begin the build-out of our pilot facility and pre-sales of our MX-05 SUV in October,” said Mullen Technologies chairman and CEO David Michery. “We plan on completing the build-out by April 2021 and to begin assembly of certification prototypes by July 2021. These vehicles will be used for homologation, which is expected to take 16 months and be completed by May of 2022, at which time we expect to begin delivering the first vehicles to the public.”
On Oct. 1, Mullen began work to turn its Monrovia, California-based, high-voltage battery R&D center into a state-of-the-art pilot facility where its line of fully electric SUVs will be manufactured. Plans call for the facility to be completed by April 2021, with the first MX-05 SUVs rolling off the production line to be delivered to customers by second quarter 2022.
Mullen Technologies anticipates its remodeled manufacturing facility will produce up to 1,000 MX-05 EVs per year; the facility will also manufacture all other upcoming models, including the MX-07 and MX-03. The factory will be renovated to include general assembly and battery assembly capabilities; the structure will also house R&D and serve as a warehouse.
Also on Oct. 1, Mullen will begin accepting preorders for its MX-05 model; starting base price for the innovative vehicle starts at $55,000. In addition, the company is also taking preorders for its Dragonfly K50, a limited-production super sports car being imported under Independent Commercial Importers. Information about both vehicles, as well as how to reserve the EVs, can be found on www.MullenUSA.com or at any Mullen retail location.
In August, Net Element announced the execution of a definitive agreement to merge with privately held Mullen Technologies Inc., in a stock-for-stock reverse merger in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger company. The completion of the merger is subject to shareholder and NASDAQ approval, as well as other conditions referenced in the merger agreement.
Net Element Inc. is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the United States and selected emerging markets.
For more information, visit the company’s website at www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
A team of Georgia State scientists has received a two-year grant to further develop a tool to help psychiatrists better diagnose and treat mood disorders. The $875,110 grant was provided by the National Institute of Mental Health and it will fund studies that will make it easier for mental health professionals to quickly diagnose and treat mental health conditions with accuracy. The researchers are based at the Center for the Translational Research in Neuroimaging and Data Science (TReNDS).
TReNDS is a tri-institutional effort supported by Georgia State University, Georgia Institute of Technology, and Emory University that is focused on making better use of complex brain imaging data. The grant was awarded to Advanced Biomedical Informatics Group LLC, a startup led by Jeremy Bockholt. The tool the firm will develop is based on research by Vince Calhoun, Distinguished University Professor of Psychology, and a Georgia Research Alliance Eminent Scholar.
Calhoun holds appointments in Electrical and Computer Engineering at Georgia Tech and Neurology and Psychiatry at Emory University and is the founding director of TReNDS. He has collaborated with Calhoun, the leader of the study for more than 15 years. Calhoun and his team plan to use data from functional magnetic resonance imaging (“fMRI”) to allow psychiatrists to more accurately predict how patients will react to medication. Their algorithm would then use machine learning to analyze a patient’s fMRI scan and compare it to scans from thousands of other individuals.
By studying how individuals with the same brain activity reacted to medication, the tool could predict how a patient will likely respond to one medication versus another. This information will help psychiatrists decide which medication to prescribe to patients. At the moment, there are no biologically based clinical tools to diagnose mental illness, with conditions like bipolar disorder taking an average of six to ten years to properly diagnose.
“This tool can give clinicians an objective window into a patient’s brain, helping them make more tailored treatment recommendations. Regardless of the diagnosis, is the patient’s brain more similar to someone who responded better to mood stabilizers or to someone who responded better to antidepressants?” asks Bockholt. The two-year grant will allow the team to refine the algorithm by feeding it additional data, including scans from a diverse group of patients as well as scans from various types of fMRI machines.
Eric Verner, Associate Director of Innovation at TReNDS and Project Co-Investigator, George State University says that “on the previous data set, our tool was over 90% accurate in predicting medication outcomes, so that shows us that we’re on the right track. By training the model on more data, it should perform better on a wider variety of patients.”
“We’re focusing on a patient population that is difficult to diagnose and treat using current methods,” says Calhoun. “It can be hard to know what type of medication is warranted. This could help inform those decisions and get patients on the right medication sooner.”
It would be interesting to see how the functionality of this tool would improve when paired with the systems used to develop customized treatments by biomedical companies like Predictive Oncology (NASDAQ: POAI).
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released a shareholder letter providing a review of where POAI “stands as of today.” The letter noted that, despite a decline of stock price over the past few weeks, the company’s cash burn is stable and even trending down, and revenues are stable and trending upward. The letter notes that POAI has adequate cash for operation, as well as ability to utilize an equity line of credit of more than $10 million. The letter also provides an update on the company’s divisions: Skyline Medical, Helomics, TumorGenesis and Soluble Biotech. The letter notes that Skyline Medical is self-supporting from a cash standpoint. Helomics has launched a restructured clinical test offering to clinicians for ovarian cancer. TumorGenesis will be introducing its Ovarian Cell Line Media at the upcoming BIO-Europe Conference; the media allows researchers to isolate and successfully culture ovarian cancer cells that have previously not been cultured. Soluble Biotech has moved into a new facility that effectively quadruples its office and research space. “As you can see, a lot is happening,” said Predictive Oncology CEO Carl Schwartz in the letter. “Much is occurring under the radar. Much doesn’t make for a press release. However, don’t be discouraged by the lack of ‘blockbuster’ announcements. We are moving forward rapidly, and we expect the fourth quarter to be eventful.”
To view the full press release, visit http://ibn.fm/lbJxa
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, has reached what it calls as a critical milestone. The company announced the lock-in of final design specifications for the commercial production model of its proprietary, next-generation Ultra Shear Technology(TM)-based nanoemulsification system. In addition, PBIO has begun initial commercial system development of the system. Once the alpha unit has been tested and approved, the company will begin building an additional 15 ready-for-sale systems. This strategy aligns with PBIO’s objective of shipping the BaroShear K45 UST System in early 2021. Based on a patented UST platform, BaroShear K45 is a proprietary nanoemulsification system that resolves a significant challenge faced by manufacturers of biotherapeutic drugs, nutraceuticals (including hemp-derived CBD products) and other products containing oil-based active ingredients: the difficulty humans have in accessing and absorbing active ingredients within oil drops. Poor water solubility makes designing and delivering proper dosing problematic. “The data generated over the past 18 months with both our bench-top and floor model prototypes have validated the ability of our revolutionary UST platform to create high quality, highly stable nanoemulsions of oil and water,” said PBIO president and CEO Richard T. Schumacher in the press release. “These exciting results support our belief that our revolutionary UST platform can help a diverse range of customers develop a vast array of new and beneficial products across many multi-million and multi-billion dollar markets, including hemp-derived CBD and other nutraceuticals, cosmetics and topical treatments, food and beverages , and biotherapeutic drugs – such as in the example of Prednisone above. We look forward with excitement to the upcoming commercial release of our revolutionary UST-based BaroShear K45 nanoemulsification system by early (Q1/Q2) 2021.”
To view the full press release, visit http://nnw.fm/0PVpl
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://nnw.fm/PBIO
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D metal printing industry, today announced the launch of its newest product, the PrintRite3D Lite In-Process Quality Assurance system, for which it was awarded its first contract from Coherent Inc. (NASDAQ: COHR), one of the world’s leading providers of lasers and laser-based technology for scientific, commercial and industrial customers. The latest addition to the PrintRite3D suite of products, PrintRite3D(R) Lite IPQA(R) features Sigma’s patented and proven TED (Thermal Energy Density) metric and was designed and developed specifically to fulfill the need for melt pool quality monitoring for the small, compact, entry-level machines used in academia, R&D, dental and industrial small-lot production. “We are very pleased to announce the launch of our new PrintRite3D Lite product as we begin implementation on the Coherent CREATOR metal 3D printer,” Mark Ruport, president and CEO of Sigma Labs, said in the news release. “PrintRite3D Lite is a great solution for 3D metal printing companies and end-user manufacturers that do not require the full functionality of PrintRite3D and increases our addressable market. PrintRite3D Lite will be available for OEM licensing as well as third party retrofit installations.”
To view the full press release, visit: https://nnw.fm/D0WEX
About Sigma Labs Inc.
Sigma Labs is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D(R) brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D for 3D metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process and informs the production manager of quality issues. Sigma Labs believes its software product will be a major catalyst for the acceleration and adoption of 3D metal printing. For more information, please visit www.SigmaLabsInc.com.
NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://nnw.fm/SGLB
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
- Processa Pharmaceuticals aims to develop products where existing clinical evidence of efficacy already exists in the targeted unmet medical need condition with the drug itself or a drug with very similar pharmacology
- The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete
- Processa’s current development pipeline features multiple clinical drug candidates, given the recent acquisitions of three additional development-focused licensing agreement since June 2020
- In total, the company’s combined scientific, development and regulatory experience has resulted in more than 30 drug approvals by the U.S. Food and Drug Administration
Processa Pharmaceuticals (NASDAQ: PCSA) aims to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions. In support of this goal, the company has assembled an unparalleled management team, board of directors and product development team featuring experts in developing drug products, from IND-enabling studies to NDA submission. In total, the team’s combined scientific, development and regulatory experience has resulted in more than 30 drug approvals by the U.S. Food and Drug Administration (“FDA”) and more than 100 meetings with the FDA while working on more than 50 drug development programs, including drug products targeted to orphan disease and unmet medical need conditions.
Headquartered in Hanover, Maryland, Processa has built a pipeline of drugs which already have some proof-of-concept clinical data supporting clinical use in their selected indications.
Development Pipeline
The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete. More specifically, Processa:
- Acquires drugs that already have some clinical data to support the targeted treatment – whether it be the drug itself, an analog of the drug or a drug with similar pharmacological targets;
- Navigates through the FDA, collaborating with the reviewers to define a complete development program; and
- Develops each drug over the course of 2-5 years, out-licensing the drug either just prior to pivotal study after Phase 2b or after the completion of the pivotal study.
Processa’s current development pipeline features multiple drug candidates, including PCS499 and PCS100. The company has also announced three additional licensing agreements since June 2020, further bolstering its clinical efforts. Each drug is briefly described below.
PCS6422
On August 27, 2020, Processa announced its entry into a contingent precedent exclusive licensing agreement with Elion Oncology Inc. to develop, manufacture and commercialize eniluracil (PCS6422) globally. PCS6422 is an oral drug to be administered with fluoropyrimidine cancer drugs (e.g., capecitabine, 5-FU) to decrease the breakdown of the cancer drug to inactive metabolites or metabolites that are known to cause unwanted side effects and to increase the anti-cancer related metabolites.
An IND for a Phase 1B study was cleared by the FDA in May 2020. The study will evaluate the safety and tolerability of several dose combinations of PCS6422 and capecitabine in advanced GI tumor patients. Processa intends to enroll the first patient in 1H2021, obtain interim results, and have a final report completed in 2H2022.
“Having worked on 5-FU and other cancer agents in the past, adding PCS6422 to our pipeline and expanding our involvement in oncology was an easy decision given the significant impact that PCS6422 may have on improving the efficacy and safety of capecitabine or other fluoropyrimidines,” CEO Dr. David Young said of the agreement.
PCS499
PCS499 as a potential treatment for necrobiosis lipoidica (“NL”) was first presented to the FDA in a pre-IND meeting in 2018. In 2019, it was the subject of an IND submission and a promising Phase 2 safety study. On March 30, 2020, Processa announced a successful meeting with the FDA regarding the design and execution of the next clinical study to evaluate the ability of PCS499 to completely close ulcers in patients with NL.
“We are pleased with the outcome of the FDA meeting and the feedback we received from the FDA. We believe that the results from our completed Phase 2 trial in NL patients, especially those with more severe ulcerated forms of NL, are encouraging and we appreciate the guidance provided by the FDA regarding our next clinical trial and the requirements to support our NDA submission,” Dr. David Young, CEO of Processa, stated in the news release.
NL is a chronic, disfiguring condition affecting the skin and tissue under the skin, typically on the lower extremities, with no currently FDA-approved treatments. More severe complications can occur, such as deep tissue infections and osteonecrosis, threatening the life of the limb. Approximately 22,500 – 55,500 people in the United States and more than 150,000 – 400,000 people worldwide are affected by the ulcerated form of NL.
YH12852
On August 20, 2020, Processa announced its entry into an agreement with Yuhan Corporation, a South Korean firm, to license YH12852, a small molecule drug in development for the treatment of functional gastrointestinal (“GI”) disorders. Under the terms of the agreement, Processa will acquire the rights to a portfolio of patents with an exclusive license to develop, manufacture and commercialize YH12852 globally, excluding South Korea.
YH12852 is a novel, potent and highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. Other 5-HT receptor agonists with less 5-HT4 selectivity have been shown to successfully treat GI mobility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia and gastroparesis. The less selective 5-HT4 agonists, such as cisapride, have been removed from the market because of the cardiovascular side effects associated with the drugs binding to other receptors, especially 5-HT receptors other than 5-HT4.
CEO Dr. David Young called the agreement “further evidence of Processa’s commitment to seek out novel treatments for unmet medical conditions.” Processa intends to meet with the FDA in early 2021 to further define the clinical development program. In 2021, Processa expects to initiate a Phase 2 trial in a functional GI motility-related disorder that that needs better therapeutic options, such as postoperative ileus and opioid-induced constipation.
ATT-11T
On June 1, 2020, Processa announced its entry into a licensing agreement with Aposense Ltd. for the patent rights and know-how to develop and commercialize ATT-11T, a next generation irinotecan cancer drug. In the release, CEO Dr. David Young noted that the licensing deal fit with Processa’s strategy to “continue to bring innovative products to patients with an unmet medical need condition.”
ATT-11T is a novel lipophilic anti-cancer pro-drug that is being developed for the treatment of the same solid tumors as prescribed for irinotecan. This pro-drug is a conjugate of a specific proprietary Aposense molecule connected to SN-38, the active metabolite of irinotecan. The proprietary Aposense molecule on ATT-11T allows ATT-11T to bind to cell membranes to form an inactive pro-drug depot on the cell, with SN-38 preferentially accumulating in the membrane of tumors cells and the tumor core. This unique characteristic is expected to make the therapeutic window of ATT-11T wider than irinotecan, such that the anti-tumor effect of ATT-11T will occur at a much lower dose than irinotecan with a milder adverse effect profile than irinotecan. The wider therapeutic window will likely lead to more patients responding with less side effects when on ATT-11T compared to irinotecan.
The ATT-11T licensing agreement is conditioned upon Processa’s closing of a satisfactory financing round and the listing of the company’s shares on the Nasdaq or NYSE, among other conditions.
PCS100
On September 3, 2020, Processa announced its entry into an exclusive worldwide license agreement with Akashi Therapeutics to develop and commercialization Akashi’s lead drug, HT-100. Rebranded PCS100, the candidate is an anti-fibrotic, anti-inflammatory drug demonstrated to have some clinical anti-fibrotic effect in children. Processa intends to develop PCS100 first in rare adult fibrotic related diseases such as focal segmental glomerulosclerosis (“FSGS”), idiopathic pulmonary fibrosis (“IPF”) or Scleroderma, where there are still few therapeutic options.
Management Team
David Young, Pharm.D., Ph.D. is the CEO and founder of Processa. He has over 30 years of pharmaceutical research, drug development and corporate experience. Young has served in leadership roles with a number of pharmaceutical firms throughout his career, including serving as founder and CEO of Promet Therapeutics LLC since 2015 and as Chief Scientific Officer of Questcor Pharmaceuticals from 2009 to 2014. At Questcor, he was responsible for working with the FDA on modernizing the Acthar Gel label and for obtaining FDA approval in infantile spasms. In total, Young has met with the FDA more than 100 times on more than 50 drug products and has been a key team member on more than 30 NDA/supplemental NDA approvals.
Sian Bigora, Pharm.D., is Processa’s Chief Development Officer and founder. She has over 20 years of pharmaceutical research, regulatory strategy and drug development experience, working closely with Young. Prior to joining Processa, Bigora served as Co-Founder, Director and Chief Development Officer at Promet Therapeutics LLC and as Vice President of Regulatory Affairs at Questcor Pharmaceuticals from 2009 to 2015, where she led efforts to modernize the Acthar Gel label and obtain FDA approval in infantile spasms – events which were of material importance to Questcor’s subsequent success.
Patrick Lin is Chief Business & Strategy Officer and founder of Processa. He has over 20 years of financing and investing experience in the biopharma sector. Prior to joining Processa, Lin served as Co-Founder and Chairman of Promet Therapeutics LLC. He is also founder and managing partner of Primarius Capital, a family office that manages public and private investments focused on small capitalization companies.
James Stanker has served as CFO of Processa since 2018. He has over 30 years of financial and executive leadership experience in the areas of accounting principles and audit standards, regulatory reporting, and fiscal management and strategy. He served in a financial leadership role as an audit partner at Grant Thornton from February 2000 until his retirement in August 2016, where he was responsible for managing audit quality in the Atlantic Coast market territory.
Wendy Guy is the Chief Administrative Officer and founder of Processa. She has more than two decades of experience in business operations, having worked closely with Young over the last 18 years in corporate management and operations, HR and finance. Prior to joining Processa, she was Co-Founder, Director and Chief Administrative Officer of Promet Therapeutics LLC and Senior Manager, Business Operation over the Maryland office for Questcor Pharmaceuticals.
For more information, visit the company’s website at www.ProcessaPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Youngevity International (NASDAQ: YGYI), a leading multichannel lifestyle company operating in three distinct business segments, on Friday announced its receipt of a September 29, 2020, Staff Determination Letter (the “September Notification”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC. According to the update, the letter indicated that Youngevity did not meet the terms of the exception previously granted to it by Nasdaq (the “Exception”) pursuant to the notification letter received by the company on August 11, 2020. Under the Exception, in order to regain compliance with Nasdaq Listing Rule 5250(c)(1), the company was obligated to have filed its annual report on Form 10-K for the year ended December 31, 2019, its quarterly report on Form 10-Q for the quarter ended March 31, 2020, and its quarterly report on Form 10-Q for the quarter ended June 30, 2020 (the “Delinquent Filings”) by September 28, 2020. The September Notification also provided that the company would be subject to suspension unless it timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”). Accordingly, the company intends to timely request a hearing before the Panel. In addition, on September 29, 2020, the company received a notification from Nasdaq staff stating that it has fallen below the $1.00 minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) based on the closing bid price of the company’s common stock for the previous 30 consecutive trading days. The company has a period of 180 calendar days in which to regain compliance prior to any further action being taken by Nasdaq. If at any time during this 180-day period the closing bid price of the company’s common stock is at least $1.00 for a minimum of 10 consecutive business days, the company may be deemed to have regained compliance with Rule 5550(a)(2). Youngevity International intends to regain compliance with the minimum bid price requirement of Rule 5550(a)(2) within the 180-day compliance period, though there can be no assurance that it will be able to do so.
To view the full press release, visit http://nnw.fm/ZXklh
About Youngevity International Inc.
Youngevity International is a multichannel lifestyle company operating in three distinct business segments including a commercial coffee enterprise, a commercial hemp enterprise and a multivertical omni direct-selling enterprise. The company features a multi-country selling network and has assembled a virtual Main Street of products and services under one corporate entity. YGYI offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, as well as innovative services. For investor information, visit the company’s website at www.YGYI.com.
NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://nnw.fm/YGYI
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
- Pharmaceutical services innovator Trxade Group Inc. has gained investor attention as it has emerged as a responsive healthcare market force during the ongoing COVID-19 pandemic
- As the pandemic began to unfold earlier this year, Trxade Group saw revenues jump effectively to three times their previous Q1 level, largely as a result of personal protective equipment products
- The company’s core mission has been to help small, community-centered retail pharmacies compete with large national chains through prescription drug price transparency and AI-driven protocols that help pharmacies stay abreast of what’s available
- Trxade Group’s advances in delivering services ranging from consultation to drug shipping via virtual, remote-access technology has kept it abreast of developments as the effects of the pandemic have led to social-distancing limitations
The surprise manifestation of the novel COVID-19 coronavirus and its spread as a global pandemic this year has led to a cascade of changes involving how health care is administered, perhaps most notably in the increased adoption of telehealth services.
Telehealth services have been ideally situated for meeting remote access needs amid conditions in which the potential spread of a highly contagious virus has led medical policy makers to discourage close contact between people and gatherings in large numbers, especially indoors.
Five hundred healthcare industry executives surveyed by marketing agency Boston Digital recently reported the growing use of telehealth amid the pandemic has delivered largely positive results and the majority of the respondents said some of the changes in care protocols would undoubtedly remain in effect after the pandemic ends (https://nnw.fm/QA4TV).
Integrated pharmaceutical services innovator Trxade Group (NASDAQ: MEDS) has seen growing enthusiasm about its business profile during the course of the pandemic, largely because of revenue growth that has far exceeded expectations. The Q2 report showed a more-than-triple increase year-over-year to $6.6 million, practically tripling sequentially after Q1 this year as reported in a July earnings call (https://nnw.fm/N0lsL), which sent the stock soaring 35 percent immediately after the announcement, as noted in a Q3 research summary (https://nnw.fm/X1aPJ).
The company’s artificial intelligence API is designed to streamline the transfer of information between healthcare industry businesses. Trxade’s model thereby helps smaller, independent pharmacies in particular to competitively serve patients in spite of the proliferation of large pharmaceutical chains.
But Trxade is also rolling out a first-of-its-kind bundled service that combines telehealth performance, a COVID-19 risk assessment tool and a personal protective equipment (PPE) purchasing tool. The bundled service will help businesses better deal with the medical needs of their internal corporate structures during the changing conditions as well as once the pandemic conditions have ended.
Trxade has been working to build its capital since uplisting to the Nasdaq exchange earlier this year (https://nnw.fm/idY9H) and more recently gaining inclusion on this year’s Russell’s Microcap Index (https://nnw.fm/tFNLb). The company has also brought international investor relations specialists MZ Group on board to expand the company’s strategic investor relations program across all key markets.
The growing brand in the medical technology space has attracted nearly 11,700 independent pharmacies to its network — more than 50 percent penetration among the United States’ estimated 22,000 independent pharmacies.
“Our platform lets these independents know that they’re receiving a fair price from competing suppliers on fair payment terms and often with next day delivery,” Founder, Chairman and CEO Suren Ajjarapu said during the earnings conference call. “We believe this radical price transparency, economy of scale and competition amongst suppliers leads (to) up to 10% reduction in pharmacies’ total annual drug purchase costs, with a drug-level savings of up to 90% on certain pharmaceutical products.”
For more information, visit the company’s website at www.TrxadeGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, has achieved several significant milestones as of late. These include the company’s receipt of permit approval to accept debris and manufacture mulch at its largest facility, located in Jacksonville (http://nnw.fm/yw8vR). “We are very pleased with our performance and direction,” stated SGTM CEO and director Tony Raynor in a recent article discussing the permit and SGTM’s financial results for the second quarter of 2020. “The positive recorded numbers were generated prior to achieving IPEMA certification for public surfacing material, which diversified our revenue stream; prior to construction at our Waste Management landfill facility, which further increased mulch manufacturing; and prior to the addition of new grapple hauling trucks to our fleet, which increased efficiency and production. The subsequent events look to lead us to another positive quarter, and we look forward to seeing how it all unfolds.”
To view the full article, visit: https://nnw.fm/HMTqm
About Sustainable Green Team Ltd.
Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris, which has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting tree debris through its tree services division and collection sites and then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic-growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential and commercial clients.
For additional information regarding SGTM’s operations, expansion plans and production facilities, view the company’s presentation. For more information about the company’s Mulch Manufacturing subsidiary, visit www.MulchMfg.com.
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://nnw.fm/SGTM
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
